PUBLISHER: IMARC | PRODUCT CODE: 1378880
PUBLISHER: IMARC | PRODUCT CODE: 1378880
The global ADME toxicology testing market size reached US$ 8.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 17.4 Billion by 2028, exhibiting a growth rate (CAGR) of 13.6% during 2022-2028.
Absorption, distribution, metabolism and excretion (ADME) toxicology testing is conducted at an early phase of the drug development process to determine the safety, uptake, elimination, effectiveness and metabolic behavior of a parent compound or drug in living organisms. It is generally carried out by researchers in cell-based and in vitro assays using software solutions, devices, detectors, etc. to identify active compounds, genetic interactions and other biomolecular interactions. It helps in understanding the safety and toxicity of a drug candidate before progressing it into a late stage preclinical and clinical studies, thereby saving cost, drug discovery time and test complications.
The growing prevalence of diseases is increasing the requirement of novels drugs and biological products. This represents one of the key factors escalating the adoption of ADME toxicology testing to prevent the failure of candidate drugs at late-stage clinical trials.111 It also helps researchers to determine the viability of these drugs necessary for regulatory approval. Additionally, one of the key trends witnessed in the market is the introduction of several guidance documents by the Food and Drug Administration (FDA) to provide instruction about ADME properties when evaluating the safety and efficacy of a drug candidate. Apart from this, the introduction of software that can calculate ADME automatically is gaining traction over conventional in vitro assays and in vivo experiments. Furthermore, due to the mass outbreak of the coronavirus disease (COVID-19) and a significant lack of an effective vaccine or treatment, ADME toxicology testing is being utilized to calculate the efficacy of existing drugs as an alternative treatment, which is also augmenting the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global ADME toxicology testing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on technology, product type, method and application.
Cell Culture
High Throughput Screening
Molecular Imaging
OMICS Technology
Others
Instruments
Software Solutions
Assay Systems
Reagents
Others
In-Vivo
In-Vitro
In-Silica
Others
Systemic Toxicity
Renal Toxicity
Hepatotoxicity
Neurotoxicity
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Beckman Coulter Inc. (Danaher Corporation), Bioivt LLC, Bio-Rad Laboratories Inc., Charles River Laboratories International Inc., Cyprotex Plc (Evotec AG), Molecular Discovery Ltd., Perkinelmer Inc., Promega Corporation and Thermo Fisher Scientific Inc.